Literature DB >> 35070398

Impact of postoperative lymph node status on the prognosis of esophageal squamous cell carcinoma after esophagectomy following neoadjuvant chemoradiotherapy: a retrospective study.

Zhiyong Sun1, Xin Xu2, Xiaojing Zhao1, Xiumei Ma2, Qing Ye1.   

Abstract

BACKGROUND: Neoadjuvant chemoradiotherapy (nCRT) and surgery are widely used treatments for locally advanced esophageal squamous cell carcinoma (ESCC). Thus, it is critically important to investigate risk factors that affect patient prognosis after preoperative chemoradiotherapy and surgery.
METHODS: We conducted a retrospective analysis of 77 patients with ESCC who received nCRT and underwent surgery at our center from January 2015 to December 2019. We analyzed the primary clinical data, postoperative pathological results, recurrence, and death results.
RESULTS: Among the 77 ESCC patients who received nCRT and surgery, 19 achieved a postoperative pathologic complete response (pCR), and the overall pCR rate was 24.68%. The univariate analysis indicated that postoperative post-neoadjuvant treatment N stage (ypN) metastasis [hazards ratio (HR): 2.908; 95% confidence interval (CI): 0.874-9.676; P=0.082], a high lymph-node ratio [(LNR) >0.1] (HR: 7.149, 95% CI: 1.740-29.369; P=0.006), post-neoadjuvant treatment T3-4 (ypT3-4) (HR: 3.626, 95% CI: 0.824-15.956; P=0.088) affected disease-specific survival (DSS). The multivariate analysis indicated that a high LNR (>0.1) (HR: 6.170; 95% CI: 1.472-25.856; P=0.013) was a significant independent predictor of DSS. The univariate analysis indicated that postoperative ypN metastasis (HR: 2.283; 95% CI: 1.047-4.979; P=0.038) and a high LNR (>0.1) (HR: 4.210; 95% CI: 1.547-11.458; P=0.005) were associated with recurrence-free survival (RFS). The multivariate survival analysis showed that a high LNR (>0.1) (HR: 4.289; 95% CI: 1.538-11.965; P=0.005) was also a significant independent predictor of RFS. In this study, 57 positive lymph nodes were found in 30 of the 77 patients, including 16 left gastric lymph nodes, 9 pericardial lymph nodes, and 7 left supraclavicular lymph nodes.
CONCLUSIONS: A high LNR (>0.1) in ESCC patients after nCRT is a risk factor of DSS and RFS. ypN metastasis is also an independent predictor of RFS. Left gastric-arterial lymph nodes, para-cardiac lymph nodes, and left supraclavicular lymph nodes are the most common sites of metastasis in ESCC after nCRT. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Esophageal squamous cell carcinoma (ESCC); lymph nodes; lymph-node ratio (LNR); neoadjuvant chemoradiotherapy (nCRT); prognosis

Year:  2021        PMID: 35070398      PMCID: PMC8748053          DOI: 10.21037/jgo-21-807

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  20 in total

1.  Node status in transmural esophageal adenocarcinoma and outcome after en bloc esophagectomy.

Authors:  J J Nigro; S R DeMeester; J A Hagen; T R DeMeester; J H Peters; M Kiyabu; G M Campos; S Oberg; O Gastal; P F Crookes; C G Bremner
Journal:  J Thorac Cardiovasc Surg       Date:  1999-05       Impact factor: 5.209

2.  Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors?

Authors:  Elfriede Bollschweiler; Stephan E Baldus; Wolfgang Schröder; Paul M Schneider; Arnulf H Hölscher
Journal:  J Surg Oncol       Date:  2006-10-01       Impact factor: 3.454

3.  Predicting the Future Burden of Esophageal Cancer by Histological Subtype: International Trends in Incidence up to 2030.

Authors:  Melina Arnold; Mathieu Laversanne; Linda Morris Brown; Susan S Devesa; Freddie Bray
Journal:  Am J Gastroenterol       Date:  2017-06-06       Impact factor: 10.864

Review 4.  Does neoadjuvant chemoradiotherapy increase survival in patients with resectable oesophageal cancer?

Authors:  Silviu I Buderi; Michael Shackcloth; Richard D Page
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-09-13

5.  Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer.

Authors:  P van Hagen; B P L Wijnhoven; P Nafteux; J Moons; K Haustermans; G De Hertogh; J J B van Lanschot; T Lerut
Journal:  Br J Surg       Date:  2012-11-23       Impact factor: 6.939

6.  Prognostic significance of preoperative lymph node assessment for patients with stage pN0 esophageal squamous cell carcinoma after esophagectomy.

Authors:  Yan Shi; Jinming Xu; Ying Wang; Jie Tang; Chong Zhang; Wang Lv; Jian Hu
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

7.  Impact of pathological complete response following neoadjuvant chemoradiotherapy in esophageal cancer.

Authors:  Tamer Soror; Gerlinda Kho; Kuai-Le Zhao; Mahmoud Ismail; Harun Badakhshi
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

8.  Pretreatment CT and 18 F-FDG PET-based radiomic model predicting pathological complete response and loco-regional control following neoadjuvant chemoradiation in oesophageal cancer.

Authors:  Anupam Rishi; Geoffrey G Zhang; Zhigang Yuan; Austin J Sim; Ethan Y Song; Eduardo G Moros; Michal R Tomaszewski; Kujtim Latifi; Jose M Pimiento; Jacques-Pierre Fontaine; Rutika Mehta; Louis B Harrison; Sarah E Hoffe; Jessica M Frakes
Journal:  J Med Imaging Radiat Oncol       Date:  2020-12-01       Impact factor: 1.735

9.  Usefulness of positron emission tomography-computed tomography in pre-operative evaluation of intra-thoracic esophageal cancer.

Authors:  Jae Jun Kim; Jae Kil Park; Seok Whan Moon
Journal:  Thorac Cancer       Date:  2015-03-06       Impact factor: 3.500

10.  Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.

Authors:  Hong Yang; Hui Liu; Yuping Chen; Chengchu Zhu; Wentao Fang; Zhentao Yu; Weimin Mao; Jiaqing Xiang; Yongtao Han; Zhijian Chen; Haihua Yang; Jiaming Wang; Qingsong Pang; Xiao Zheng; Huanjun Yang; Tao Li; Florian Lordick; Xavier Benoit D'Journo; Robert J Cerfolio; Robert J Korst; Nuria M Novoa; Scott J Swanson; Alessandro Brunelli; Mahmoud Ismail; Hiran C Fernando; Xu Zhang; Qun Li; Geng Wang; Baofu Chen; Teng Mao; Min Kong; Xufeng Guo; Ting Lin; Mengzhong Liu; Jianhua Fu
Journal:  J Clin Oncol       Date:  2018-08-08       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.